Table 2.

Baseline Patient and Tumor Molecular Characteristics

Characteristic	All Patients (N = 37)		AUY922 (25 to 55 mg/m2; n = 12)		AUY922 (70 mg/m2; n = 25)*
	No.	%	No.	%	No.	%
Female sex	27	73	9	75	18	72
Age, years
Median	59		62		58
Range	30-76		30-76		42-76
Never-smoker	26	70	8	67	18	72
ECOG performance status
0	14		5		9
1	20		5		15
2	3		2		1
Race/ethnicity
White	20		5		15
Asian	13		5		8
Black	4		2		2
Primary EGFR mutation
Exon 19 deletion	25		10		15
Exon 21 L858R	11		2		9
Exon 21 L861Q	1		0		1
EGFR T790 mutation on repeat tumor biopsy	16	43	6	50	10	40
Prior lines of therapy, months
Median	2		2		2
Range	1-7		1-4		1-7
Duration of EGFR TKI before developing AR, months
Median	12		13		11
Range	2-42		8-32		2-42
Receiving any EGFR-directed therapy immediately before trial†	36		12†		24
Receiving erlotinib monotherapy immediately before trial	22		10		11
Newly diagnosed AR at enrollment	8		2		6
T790 mutation in patients with newly diagnosed AR	5		2		3
Patients with previously diagnosed AR	29		10		19
T790 mutation in patients with previously diagnosed AR	12		5		7

Abbreviations: AR, acquired resistance; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.

^*Including six patients from phase I treated at maximum-tolerated dose.

^†Erlotinib containing in every case except one patient treated with afatinib plus cetuximab.